Highest-materiality recent filing
AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M
Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
AVITA Medical appoints Cary Vance as permanent CEO, Jan Stern Reed as Board Chair
Cary Vance named President and CEO effective April 30, 2026; served as Interim CEO since October 2025.
AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M
Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).
AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M
Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.
AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M
Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.
AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M
CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.
AVITA Medical raises ~$15M via placement of 17.2M CDIs at AU$1.32 each
Issued 17.2M CHESS Depositary Interests (CDIs) at AU$1.32/CDI; 5 CDIs = 1 common share.
Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.
AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M
Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.
AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%
10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.
AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M
Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.
AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025
Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.
AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches
Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.
AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M
Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).
Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.
AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device
FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.
AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end
Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.
AVITA Medical cuts Q1 2024 revenue guidance to $11.0-$11.3M from prior $14.8-$15.6M
Expected Q1 commercial revenue $11.0M-$11.3M vs prior guidance $14.8M-$15.6M.
AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M
Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%.
AVITA reports preliminary FY2023 revenue $49.8M (+46% YoY), signs PermeaDerm distribution deal
Q4 2023 commercial revenue ~$14.1M (+50% YoY); full-year 2023 commercial revenue ~$49.8M (+46% YoY).
AVITA Medical Q3 commercial revenue up 51% to $13.5M; net loss $8.7M
Commercial revenue $13.5M (+51% YoY); total revenue $13.6M; gross margin 84.5%.
AVITA Medical secures $90M debt facility from OrbiMed; prelim Q3 revenue $13.5M (+50% YoY)
Preliminary Q3 commercial revenue $13.5M, +50% YoY from ~$9.0M; gross margin ~84.5%.
AVITA Medical receives FDA additional info request for RECELL GO PMA; launch pushed to mid-2024
FDA placed RECELL GO PMA supplement on hold for ~4-6 months pending additional info.
Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.
AVITA Medical reveals ~391K annual eligible procedures after expanded RECELL FDA approval
Expanded FDA indication for full-thickness skin defects opens ~391,000 annual eligible procedures.
AVITA Medical names David O'Toole CFO; $450K salary, 150K options
David O'Toole appointed CFO effective June 15, 2023; brings 30+ years biotech/life sciences finance experience.
AVITA Medical Q1 commercial revenue up 40% to $10.5M; reaffirms FY guidance; CCO resigns
Commercial revenue $10.5M (+40% YoY); total revenue $10.6M (+40%); gross margin 84% vs 76%.
CFO Michael Holder and COO Kathy McGee leaving Avita Medical effective Jan 19, 2023.
AVITA Medical submits FDA PMA application for RECELL System to treat stable vitiligo
PMA submitted to FDA to expand RECELL indication to stable vitiligo; received Breakthrough Device designation.
AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met
Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.
the Board appointed Jan Stern Reed as Chair of the Board while simultaneously terminating the Lead Independent Director position that she had been serving since October 2025
the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief Executive Officer ("CEO"), effective April 30, 2026
On June 28, 2024, Ms. Donna Shiroma, the Company’s General Counsel, Compliance Officer and Corporate Secretary, notified AVITA Medical, Inc. (the "Company") of her retirement effective immediately.
Ms. Shiroma is succeeded by Nicole Kelsey, effective immediately, who will serve as the Company’s Chief Legal and Compliance Officer and Corporate Secretary.
AVITA Medical, Inc. (the “Company”) entered into an Executive Employment Agreement (the “Agreement”) with David O’Toole with an effective date of June 15, 2023 (the “Effective Date”), pursuant to which Mr. O’Toole will serve as the Company’s Chief Financial Officer.
Effective May 11, 2023, Ms. Erin Liberto, the Company’s Chief Commercial Officer, resigned from her position and accepted a role with a privately held, non-competitive business.
On March 23, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Robert McNamara to its Board of Directors (the “Board”), effective April 1, 2023
On March 16, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Cary Vance to its Board of Directors (the “Board”), effective April 1, 2023
Michael Holder, the Company’s Chief Financial Officer, and Kathy McGee, the Company’s Chief Operating Officer, are leaving the organization.
Mr. Holder’s responsibilities as the Company’s principal financial officer and principal accounting officer will transition to Mr. Sean Ekins, as Interim Chief Financial Officer, effective immediately.
Effective September 28, 2022, the Board of Directors of the Company appointed James Corbett as the Company’s President and CEO.
Effective September 28, 2022, the Board of Directors of Avita Medical, Inc. (the “Company”) terminated the employment of Dr. Michael Perry, the Company’s President and CEO.
Max materiality 0.85 · Median 0.65 · Most common event earnings